Home › Merck Announces Samsung Bioepis Receives Approval of RENFLEXIS (Infliximab), a Biosimilar of Remicade, in Korea
 

Keywords :   


Merck Announces Samsung Bioepis Receives Approval of RENFLEXIS (Infliximab), a Biosimilar of Remicade, in Korea

2015-12-07 14:00:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. Samsung Bioepis Second Immunology Biosimilar Approved, to be Commercialized Under Partnership with Merck KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that Samsung Bioepis Co., Ltd. has received approval of RENFLEXIS (infliximab), a biosimilar of the immunology medicine Remicade, by the Ministry of Food and Drug Safety (MFDS) in Korea. Merck will commercialize Samsung Bioepis RENFLEXIS in Korea as part of Mercks commercialization partnership with Samsung Bioepis to offer high-quality biosimilar alternatives to existing biologic medicines. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orRobert Consalvo, 908-236-1127orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: korea samsung approval receives

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.10Eastern North Pacific Tropical Weather Outlook
05.10Atlantic Tropical Weather Outlook
04.10Should you tip even if the service wasn't worth it?
04.10Hurricane Kirk Graphics
04.10Hurricane Kirk Forecast Discussion Number 22
04.10Tropical Storm Leslie Forecast Discussion Number 10
04.10Hurricane Kirk Wind Speed Probabilities Number 22
04.10Hurricane Kirk Public Advisory Number 22
More »